Citations

Clear

813 citation(s) found for "He, Helen".

The State of US Health, 1990-2016
Collaborators, The US Burden of Disease, Mokdad, Ali H. , Ballestros, Katherine, Echko, Michelle, Glenn, Scott , Olsen, Helen Elizabeth , Mullany, Erin C, Lee, Alex , Khan, Abdur Rahman , Ahmadi, Alireza , Ferrari, Alize J , Kasaeian, Amir , Werdecker, Andrea , Carter, Austin , Zipkin, Ben, Sartorius, Benn , Serdar, Berrin , Sykes, Bryan L. , Troeger, Chris, Fitzmaurice, Christina , Rehm, Colin D. , Santomauro, Damian , Kim, Daniel , Colombara, Danny V. , Schwebel, David C. , Tsoi, Derrick, Nichols, Emma , Oren, Eyal , Charlson, Fiona , Patton, George , Roth, Gregory A. , Kyu, Hmwe Hmwe , Erskine, Holly E , Huang, Hsiang , Martopullo, Ira , Nachega, Jean B. , Sanabria, Juan , Tabb, Karen M. , Krohn, Kristopher J, Cornaby, Leslie, Moses, Mark , Farvid, Maryam S. , Griswold, Max , Criqui, Michael H, Bell, Michelle L. , Nguyen, Minh , Wallin, Mitch, Mirarefin, Mojde, Younis, Mustafa Z , Fullman, Nancy , Liu, Patrick , Briant, Paul Svitil, Gona, Philimon , Havmöller, Rasmus, Kimokoti, Ruth W , Hay, Simon I , Yadgir, Simon , Biryukov, Stan, Vollset, Stein Emil, Alam, Shazia , Frank, Tahvi , Farid, Talha, Miller, Ted R. , Vos, Theo , Bärnighausen, Till , Gebrehiwot, Tsegaye, Yano, Yuichiro , Al‐Aly, Ziyad , Mehari, Alem , Handal, Alexis J. , Kandel, Amit , Anderson, Benjamin O. , Biroscak, Brian J. , Dorsey, E. Ray, Ding, Eric L. , Park, Eun‐Kee , Wagner, Gregory R. , Chen, Honglei , Sunshine, Jacob E. , Khubchandani, Jagdish , Leasher, Janet L , Leung, Janni , Unützer, Jürgen , Cahill, Leah E. , Cooper, Leslie T. , Bräuer, Michael , Breitborde, Nicholas J. K. , Topór-Mądry, Roman , Soneji, Samir , Stranges, Saverio , James, Spencer L , Amrock, Stephen M. , Jayaraman, Sudha , Skirbekk, Vegard , Kinfu, Yohannes , Bhutta, Zulfiqar A , Murray, Christopher J L , Topór‐Mądry, Roman , Bell, Max , Cooper, Leslie T , Collaborators, The US Burden of Disease, Kolte, Dhaval , Nsoesie, Elaine Okanyene , Hosgood, H. Dean, Whiteford, Harvey , Singh, Jasvinder A. , Abbas, Kaja , Ong, Sok King , Degenhardt, Louisa J , Qorbani, Mostafa , Leung, Ricky , Bazargan‐Hejazi, Shahrzad , Vollset, Stein Emil, Mozaffarian, Dariush , Hu, Guoqing , Salomon, Joshua A. , Horino, Masako , Hotez, Peter Jay , Patel, Tejas Kamleshbhai , Akinyemiju, Tomi , Jonas, Jost B , Oren, Eyal

Mayo Clinic

JAMA | April 10, 2018 | Volume: 319 | Issue: 14 | Pages: 1444

10.1001/jama.2018.0158 | PMID 29634829 Get It

Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH)
Polster, Sean P. , Flemming, Kelly D. , Girard, Romuald , Hanley, Daniel F. , Hobson, Nicholas , Kim, Helen , Koskimäki, Janne , Lane, Karen , McBee, Nichol , Stadnik, Agnieszka , Thompson, Richard E. , Zabramski, Joseph M. , Zeineddine, Hussein A. , Awad, Issam A. , Flemming, Kelly, Girard, Romuald , Hanley, Daniel F , Cao, Ying , Carroll, Timothy , Koenig, James I. , Majersik, Jennifer Juhl , Morrison, Leslie , Shenkar, Robert , Flemming, Kelly D , Kim, Helen , Polster, Sean P

Mayo Clinic

Neurosurgery | March 6, 2018 | Volume: 84 | Issue: 4 | Pages: 954-964

10.1093/neuros/nyy108 | PMID 29660039 Get It

Abstract BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much progress has been made in understanding the epidemiology of CASH, and novel biomarkers have been linked to the biological mechanisms and clinical activity in lesions. Yet, the ability to enroll and risk-stratify CASH subjects has never been assessed prospectively at multiple sites. Biomarkers and other outcomes have not been evaluated for their sensitivity and reliability, nor have they been harmonized across sites. OBJECTIVE To address knowledge gaps and establish a research network as infrastructure for future clinical trials, through the Trial Readiness grant mechanism, funded by National Institute of Neurological Disorders and Stroke/National Institutes of Health. METHODS This project includes an observational cohort study to assess (1) the feasibility of screening, enrollment rates, baseline disease categorization, and follow-up of CASH using common data elements at multiple sites, (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures that have been shown to correlate with lesion activity, and (3) the rates of recurrent hemorrhage and change in functional status and biomarker measurements during prospective follow-up. EXPECTED OUTCOMES We propose a harmonized multisite assessment of enrollment rates of CASH, baseline features relevant to stratification in clinical trials, and follow-up assessments of functional outcomes in relation to clinical bleeds. We introduce novel biomarkers of vascular leak and hemorrhage, with firm mechanistic foundations, which have been linked to clinical disease activity. We shall test their reliability and validity at multiple sites, and assess their changes over time, with and without clinical rebleeds, hence their fitness as outcome instruments in clinical trials. DISCUSSION The timing cannot be more opportune, with therapeutic targets identified, exceptional collaboration among researchers and the patient community, along with several drugs ready to benefit from development of a path to clinical testing using this network in the next 5 years.
Melanoma mimicking Rosai‐Dorfman disease
Xie, Daniel Y., Costello, Collin M. , Liang, Helen J. , Thomas, Brett G., DiCaudo, David J. , Mangold, Aaron R. , Mangold, A R , Liang, Helen J. , Costello, Collin M

Mayo Clinic

Journal of Cutaneous Pathology | February 5, 2018 | Volume: 45 | Issue: 5 | Pages: 355-359

10.1111/cup.13121 | PMID 29405342 Get It

Despite well‐defined clinical and histopathological features of melanoma, atypical presentations mimicking other skin disorders can result in a delayed diagnosis or misdiagnosis and subsequent inappropriate treatment. Rosai‐Dorfman disease (RDD) is a rare histiocytic disorder with unique clinical and histopathological features. We report a case of melanoma treated with cryotherapy that mimicked RDD both clinically and histopathologically. We compare this RDD‐like melanoma to classic RDD, outlining the importance of clinicopathological correlation prior to treatment, as well as the potential pitfalls in diagnosis after cryotherapy of pigmented lesions.
Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus
Moinova, Helen , LaFramboise, Thomas , Lutterbaugh, James, Chandar, Apoorva K., Dumot, John A. , Faulx, Ashley L., Brock, Wendy , Cabrera, Omar De la Cruz , Guda, Kishore , Barnholtz‐Sloan, Jill S. , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , De la Cruz Cabrera, Omar , Willis, Joseph E , Chak, Amitabh , Markowitz, Sanford D , Barnholtz-Sloan, Jill S , Canto, Marcia Irene

Mayo Clinic

Science Translational Medicine | January 17, 2018 | Volume: 10 | Issue: 424 | Pages: No page available

10.1126/scitranslmed.aao5848 | PMID 29343623 Get It

Combining DNA methylation markers with a swallowable device for sampling the distal esophagus effectively detects Barrett’s neoplasias.
Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats
Shah, Vijay H. , Cao, Sheng , Hendrickson, Helen, Yao, Janet , Katušić, Zvonimir S.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 280 | Issue: 6 | Pages: G1209-G1216

10.1152/ajpgi.2001.280.6.g1209 | PMID 11352814 Get It

In carbon tetrachloride-induced liver cirrhosis, diminution of hepatic endothelial nitric oxide synthase (eNOS) activity may contribute to impaired hepatic vasodilation and portal hypertension. The mechanisms responsible for these events remain unknown; however, a role for the NOS-associated proteins caveolin and calmodulin has been postulated. The purpose of this study is to characterize the expression and cellular localization of the NOS inhibitory protein caveolin-1 in normal rat liver and to then examine the role of caveolin in conjunction with calmodulin in regulation of NOS activity in cholestatic portal hypertension. In normal liver, caveolin protein is expressed preferentially in nonparenchymal cells compared with hepatocytes as assessed by Western blot analysis of isolated cell preparations. Additionally, within the nonparenchymal cell populations, caveolin expression is detected within both liver endothelial cells and hepatic stellate cells. Next, studies were performed 4 wk after bile duct ligation (BDL), a model of portal hypertension characterized by prominent cholestasis, as evidenced by a significant increase in serum cholesterol in BDL animals. After BDL, caveolin protein levels from detergent-soluble liver lysates are significantly increased as assessed by Western blot analysis. Immunoperoxidase staining demonstrates that this increase is most prominent within sinusoids and venules. Additionally, caveolin-1 upregulation is associated with a significant reduction in NOS catalytic activity in BDL liver lysates, an event that is corrected with provision of excess calmodulin, a protein that competitively binds eNOS from caveolin. We conclude that, in cholestatic portal hypertension, caveolin may negatively regulate NOS activity in a manner that is reversible by excess calmodulin.
Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro
Shah, Vijay H. , Chen, Alex F. , Cao, Sheng , Hendrickson, Helen, Weiler, Deb, Yao, Janet , Katušić, Zvonimir S. , Smith, Leslie

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 279 | Issue: 5 | Pages: G1023-G1030

10.1152/ajpgi.2000.279.5.g1023 | PMID 11053000 Get It

Endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) contributes to hepatic vascular homeostasis. The aim of this study was to examine whether delivery of an adenoviral vector encoding eNOS gene to liver affects vasomotor function in vivo and the mechanism of NO production in vitro. Rats were administered adenoviruses encoding β-galactosidase (AdCMVLacZ) or eNOS (AdCMVeNOS) via tail vein injection and studied 1 wk later. In animals transduced with AdCMVLacZ, β-galactosidase activity was increased in the liver, most prominently in hepatocytes. In AdCMVeNOS-transduced animals, eNOS protein levels and catalytic activity were significantly increased. Overexpression of eNOS diminished baseline perfusion pressure and constriction in response to the α1-agonist methoxamine in the perfused liver. Transduction of cultured hepatocytes with AdCMVeNOS resulted in the targeting of recombinant eNOS to a perinuclear distribution and binding with the NOS-activating protein heat shock protein 90. These events were associated with increased ionomycin-stimulated NO release. In summary, this is the first study to demonstrate successful delivery of the recombinant eNOS gene to liver in vivo and in vitro with ensuing NO production.
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Meehan, Terrence F. , Goldstein, Theodore C. , Murakami, Mark A. , Brabetz, Sebastian , Gu, Zhiping , Wiser, Jeffrey A., Dunn, Patrick , Begley, Dale A. , Krupke, Debra M. , Bertotti, Andrea , Bruna, Alejandra , Brush, Matthew , Byrne, Annette T. , Caldas, Carlos , Christie, Amanda L., Clark, Dominic A. , Dowst, Heidi , Dry, Jonathan R. , Doroshow, James H. , Duchamp, Olivier, Ferretti, Stéphane , Frese, Kristopher K. , Goodwin, Neal , Greenawalt, Danielle M., Haendel, Melissa , Hermans, Els , Houghton, Peter J. , Jonkers, Jos , Kemper, Kristel , Khor, Tin Oo, Lloyd, K. C. Kent , Mason, Jeremy , Médico, Enzo , Olson, James M. , Peeper, Daniel S. , Seong, Je Kyung , Trusolino, Livio , Vinolo, Emilie, Wechsler‐Reya, Robert J. , Weinstock, David M. , Welm, Alana L. , Weroha, S. John , Pfister, Stefan M. , Kool, Marcel , Parkinson, Helen , Butte, Atul J. , Bult, Carol J. , Haendel, Melissa , Caldas, Carlos , Pfister, Stefan M , Conte, Nathalie , Inghirami, Giorgio , Evrard, Yvonne A. , Lewis, Michael T. , Neuhauser, Steven B. , Rueda, Oscar M. , Amant, Frédéric

Mayo Clinic

Cancer Research | November 1, 2017 | Volume: 77 | Issue: 21 | Pages: e62-e66

10.1158/0008-5472.can-17-0582 | PMID 29092942 Get It

Abstract Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models. PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. Cancer Res; 77(21); e62–66. ©2017 AACR.
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Chinnaiyan, Prakash , Won, Minhee , Wen, Patrick Y. , Rojiani, Amyn M. , Werner‐Wasik, Maria, Shih, Helen A. , Ashby, Lynn S., Yu, Hsiang-Hsuan Michael, Stieber, Volker W. , Malone, Shawn , Fiveash, John B. , Mohile, Nimish, Ahluwalia, Manmeet S. , Wendland, Merideth M, Stella, Philip J., Kee, Andrew Y., Tsai, Ya-Yu , Shih, Helen A , Wen, Patrick Yung , Mehta, Minesh P. , Ahluwalia, Manmeet S

Mayo Clinic

Neuro-Oncology | October 30, 2017 | Volume: 20 | Issue: 5 | Pages: 666-673

10.1093/neuonc/nox209 | PMID 29126203 Get It

Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Goode, Ellen L. , Block, Matthew S. , Kalli, Kimberly R., Vierkant, Robert A. , Fogarty, Zachary C. , Tołoczko, Aleksandra, Hein, Alexander , Bouligny, Aliecia L., Jensen, Allan , Osório, Ana , Ryan, Andy , Magliocco, Anthony M., Hartmann, Arndt , Gao, Bo , McCauley, Bryan M. , Kennedy, Catherine J. , Karpinskyj, Chloe , Sousa, Christiani Bisinoto de, Tiezzi, Daniel Guimarães , Wachter, David L., Herpel, Esther , Taran, Florin‐Andrei , Nelson, Gregg , Menkiszak, Janusz , Alsop, Jennifer , Lester, Jenny , García-Donás, Jesús , Nation, Jill, Hung, Jillian A., Palacios, José , Rothstein, Joseph H. , Kelley, Joseph L., Andrade, Jurandyr Moreira de , Robles-Díaz, Luis, Intermaggio, Maria P., Widschwendter, Martin , Beckmann, Matthias W. , Ruebner, Matthias , Jimenez‐Liñan, Mercedes , Singh, Naveena , Oszurek, Oleg, Harnett, Paul R. , Rambau, Peter , Sinn, Hans‐Peter , Wagner, Philipp , Sharma, Raghwa , Ness, Roberta B., Oršulić, Sandra , Johnatty, Sharon E., Longacre, Teri A. , Eilber, Ursula, McGuire, Valerie , Sieh, Weiva , Natanzon, Yanina , Li, Zheng , Whittemore, Alice S. , DeFazio, Anna , Staebler, Annette , Bowtell, David D.L. , Høgdall, Estrid , Reis, Francisco José Cândido dos , Steed, Helen , Campbell, Ian , Benı́tez, Javier , Koziak, Jennifer M. , Chang‐Claude, Jenny, Moysich, Kirsten B. , Kelemen, Linda E. , Goodman, Marc T. , García, María J. , Fasching, Peter A. , Kommoss, Stefan , Deen, Suha , Menon, Usha , Chenevix‐Trench, Georgia , Huntsman, David G. , Köbel, Martin , Ramus, Susan J. , Winham, Stacey J. , Fazio, Anna de , Ramus, Susan J , Köbel, Martin , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Campbell, Ian G , García-Donas, Jesús , Kennedy, Catherine J , Menkiszak, Janusz , Sinn, Peter , Widschwendter, Martin , Fogarty, Zachary C , Sieh, Weiva , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Estrid , Bowtell, David D , Chen, Wenqian , Gentry‐Maharaj, Aleksandra , Bouligny, Aliecia, Hartkopf, Andreas D , Chudecka-Glaz, Anita Monika , Jung, Audrey , Hernandez, Brenda Y. , Fridley, Brooke L. , Wang, Chen , Modugno, Francesmary , Lubiński, Jan , Robles-Díaz, Luis, Ghatage, Prafull , Edwards, Todd , Brucker, Sara Yvonne , Karlan, Beth Y. , Gilks, C. Blake , Gronwald, Jacek , Cook, Linda S. , Kjær, Susanne K. , Brenton, James D. , Pharoah, Paul D.P. , Nelson, Gregg S , Harnett, Paul R , Steed, Helen , Goodman, Marc T

Mayo Clinic

JAMA Oncology | October 19, 2017 | Volume: 3 | Issue: 12 | Pages: e173290

10.1001/jamaoncol.2017.3290 | PMID 29049607 Get It

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)
Moriarty, James P. , Dusetzina, Stacie B. , Himelstein, Andrew L., Foster, Jared C. , Grubbs, Stephen S., Novotny, Paul J. , Shapiro, Charles L. , Dusetzina, Stacie, Borah, Bijan J. , Dusetzina, Stacie

Mayo Clinic

Journal of Clinical Oncology | October 12, 2017 | Volume: 35 | Issue: 35 | Pages: 3949-3955

10.1200/jco.2017.73.7437 | PMID 29023215 Get It

Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases. Methods Using a Markov model, costs per SRE avoided were calculated for the three treatments. Sensitivity analyses were performed where denosumab SRE probabilities were assumed to be 50%, 75%, and 90% lower than the ZA SRE probabilities. Quality-adjusted life-years were also calculated. The analysis was from the US payer perspective. Results The mean costs of the denosumab treatment strategy are nine-fold higher than generic ZA every 3 months. Quality-adjusted life-years were virtually identical in all the three treatment arms; hence, the optimal treatment would be ZA every 3 months because it was the least costly treatment. The sensitivity analyses showed that relative to ZA every 3 months, the incremental costs per mean SRE avoided for denosumab ranged from $162,918 to $347,655. Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab. This analysis was one of the first to incorporate the costs of generic ZA and one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively. ZA every 3 months is the more CE option and more reasonable alternative to monthly denosumab.